China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

In 2024, almost ****** U.S. dollars were spent per diabetic patient in the United States, making it the country with the second-highest average cost per person. Switzerland had the highest per-person spending on diabetes, with over ** thousand U.S. dollars per patient. Lowest spending countries When viewing diabetes-related costs worldwide, it becomes apparent that there are significant disparities between countries. The ten countries with the lowest average annual diabetes-related health expenditures per person were all African and Asian countries. The Bangladesh stood at the top of the list in 2024, with an average spending of about ** U.S. dollars per person. Other countries on this list included Pakistan, the Democratic Republic of the Congo, and Madagascar. Anti-diabetic revenue Revenue generated by anti-diabetic products has increased as the number of diabetics worldwide has risen. Novo Nordisk is one of the leading companies in diabetes care, with around ** percent of the company's revenue generated through its diabetes care segment.

In 2024, Pakistan had the highest prevalence of diabetes worldwide, with around ** percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections. Costs As of 2024, there were almost *** million people worldwide who had diabetes. With such a huge number of people suffering from this disease, it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around ***** billion U.S. dollars on diabetes health expenditure in 2024. The countries with the highest spending per patient with diabetes include Switzerland, the United States, and Norway. Death Diabetes is among the leading ten causes of death worldwide, accounting for around **** million deaths in 2021. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. The risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes, followed by North America and the Caribbean.

In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

The average for 2021 based on 11 countries was 9.58 percent. The highest value was in Malaysia: 19 percent and the lowest value was in Vietnam: 6.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.

In 2024, India had the highest number of children and adolescents aged under 20 who were living with type 1 diabetes, with around 301,000 cases. At that time, an estimated 197,000 children and adolescents in the United States had type 1 diabetes. This statistic shows the countries with the highest number of children and adolescents aged 0 to 19 years with type 1 diabetes in 2024.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Global Diabetes Prevalence by Country, 2021 Discover more data with ReportLinker!

In 2021, close to ** percent of the population in Pakistan had diabetes. In comparison, Vietnam had the lowest prevalence of diabetic people across the Asia-Pacific region that year, approximately *** percent.

Diabetes Treatment Market Outlook

According to our latest research, the global Diabetes Treatment Market size reached USD 82.6 billion in 2024, driven by rising diabetes prevalence and ongoing innovation in therapeutic approaches. The market is expected to expand at a CAGR of 6.5% from 2025 to 2033, projecting a value of approximately USD 145.2 billion by 2033. This robust growth trajectory is primarily attributed to escalating patient populations, advancements in drug delivery mechanisms, and increased awareness around diabetes management.

One of the most significant growth factors for the diabetes treatment market is the global surge in diabetes incidence, particularly Type 2 diabetes. Sedentary lifestyles, unhealthy dietary patterns, and rising obesity rates are fueling the expansion of the diabetic population, especially in emerging economies. The World Health Organization estimates that over 537 million adults were living with diabetes in 2024, a number expected to rise sharply in the coming years. This expanding patient base is generating heightened demand for both insulin and non-insulin therapies, as well as for innovative monitoring and delivery solutions. Pharmaceutical companies are responding by accelerating research and development efforts, resulting in a robust pipeline of new products and combination therapies that address the evolving needs of diabetic patients.

Technological advancements are another powerful driver in the diabetes treatment market. The introduction of next-generation insulin analogs, continuous glucose monitoring (CGM) systems, and smart insulin pens has revolutionized diabetes care, offering patients improved glycemic control and enhanced quality of life. The integration of digital health tools and telemedicine platforms is further transforming disease management, enabling real-time monitoring, personalized treatment adjustments, and improved patient engagement. These innovations are not only improving clinical outcomes but also reducing the burden on healthcare systems by minimizing complications and hospitalizations. As a result, the adoption of advanced diabetes management solutions is accelerating across both developed and developing regions.

Government initiatives and supportive reimbursement policies are also playing a pivotal role in market growth. Many countries are prioritizing diabetes care within their public health agendas, allocating substantial resources for early diagnosis, patient education, and subsidized access to essential medications. Strategic collaborations between public and private stakeholders are fostering the development and distribution of affordable treatment options, particularly in low- and middle-income countries. Additionally, the increasing availability of generic drugs and biosimilars is enhancing market accessibility, further driving the adoption of diabetes therapies worldwide. These collective efforts are expected to sustain the momentum of the diabetes treatment market over the forecast period.

From a regional standpoint, North America continues to dominate the diabetes treatment market, accounting for the largest revenue share in 2024. This leadership is underpinned by a high prevalence of diabetes, robust healthcare infrastructure, and early adoption of advanced therapeutic modalities. Europe follows closely, supported by comprehensive reimbursement frameworks and a strong focus on research and innovation. However, the Asia Pacific region is emerging as the fastest-growing market, propelled by rising disease incidence, expanding healthcare access, and increasing investments by global pharmaceutical companies. The Middle East & Africa and Latin America are also witnessing steady growth, driven by improved awareness and government-led initiatives to combat diabetes.

Product Type Analysis

The Product Type segment of the diabetes treatment market encompasses insulin, oral antidiabetic drugs, non-insulin injectable drugs, and other therapies. Insulin

Global Hospital Discharges for Diabetes Cases by Country, 2023 Discover more data with ReportLinker!

Global Diabetes Mellitus Mortality by Country, 2023 Discover more data with ReportLinker!

Type-1 Diabetes Treatment Market Outlook

The global Type-1 Diabetes Treatment market size is projected to grow significantly from USD 7.2 billion in 2023 to an estimated USD 12.6 billion by 2032, at a compound annual growth rate (CAGR) of 6.5%. The market growth is primarily driven by the rising prevalence of Type-1 diabetes worldwide, coupled with advancements in medical technology and treatment methods. Additionally, increasing awareness and early diagnosis of the disease have been pivotal in expanding the market's reach.

One of the major growth factors for the Type-1 Diabetes Treatment market is the continuous development and approval of innovative insulin delivery systems. Technologies such as insulin pumps, continuous glucose monitors, and artificial pancreas systems are revolutionizing diabetes care by offering more precise and convenient methods for managing blood sugar levels. These advancements not only improve the quality of life for patients but also reduce long-term complications associated with poor blood glucose control, thereby driving market expansion.

Another significant growth driver is the increasing investment in research and development by pharmaceutical companies. Efforts to discover new treatment modalities, including non-insulin therapies and regenerative medicine approaches like pancreas and islet cell transplantation, are creating new opportunities within the market. Additionally, collaborations between academic institutions and biotech firms are accelerating the pace of innovation, bringing novel therapies closer to commercial availability.

The market is also supported by favorable government initiatives and policies aimed at improving diabetes care. Many countries are implementing national diabetes programs that include guidelines for early diagnosis, comprehensive care plans, and subsidies for treatment costs. These programs are essential in increasing access to effective treatments, particularly in low and middle-income countries where the burden of diabetes is rising rapidly.

In recent years, Diabetes Stem Cell Therapy has emerged as a promising area of research in the treatment of Type-1 diabetes. This innovative approach involves the use of stem cells to regenerate insulin-producing beta cells in the pancreas, potentially offering a more permanent solution to insulin dependency. Researchers are exploring various sources of stem cells, including embryonic stem cells and induced pluripotent stem cells, to develop effective therapies. The ultimate goal is to restore the body's ability to produce insulin naturally, thereby reducing or eliminating the need for external insulin administration. While still in the experimental stages, early clinical trials have shown encouraging results, paving the way for future advancements in this field.

Regionally, North America dominates the Type-1 Diabetes Treatment market, accounting for the largest share due to high healthcare expenditure, advanced healthcare infrastructure, and significant investment in diabetes research. Europe follows closely, with a strong focus on improving healthcare outcomes and increasing awareness about diabetes management. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the rising prevalence of diabetes, improving healthcare infrastructure, and increasing government initiatives to enhance diabetes care. Latin America and the Middle East & Africa also show promising growth potential, although these markets are currently smaller in size compared to North America and Europe.

Insulin Therapy Analysis

Insulin therapy remains the cornerstone of Type-1 diabetes treatment, accounting for a significant share of the market. The evolution of insulin formulations, including rapid-acting, long-acting, and intermediate-acting insulins, has provided patients with more options to tailor their treatment plans to their specific needs. Innovations such as biosimilar insulins have also made treatments more accessible by offering cost-effective alternatives to branded products. Continuous advancements in insulin delivery systems, such as smart insulin pens and pumps, are further enhancing the efficacy and convenience of insulin therapy.

Recent developments in insulin therapy include the advent of ultra-rapid-acting insulins, which aim to better mimic the body's natural insulin response to meals. These insulins provide faster onset and shorter durat

By 2050, the Western Pacific region is forecast to have the highest number of diabetic people worldwide, with some 254 million people aged between 20 and 79 years. Diabetes in the future Between 2024 and 2050, the number of diabetics is set to increase in all regions worldwide. Diabetes rates are expected to increase the most in Africa, by roughly 142 percent. Throughout this period, Europe is projected to show the smallest increase, with about 10 percent. In 2050, the countries with the highest number of diabetics are expected to be China with some 168 million and India with about 157 million. At that time, about 43 million people are projected to have diabetes in the United States. Children with type 1 diabetes In 2024, the country with the highest estimated number of children and adolescents (between the ages of 0 and 19) with type 1 diabetes was India, which had some 301 thousand diabetic children and adolescents. The United States came second with around 197 thousand. Considering the U.S. population is significantly smaller than that of India, there is a higher percentage of children with type 1 diabetes in the United States.

BackgroundAfter the declaration of the COVID-19 pandemic, governments established national lockdowns and social distancing as an effective plan to control this disease. As a result of the lockdown policies, diabetic patients` access to food products, medication, and routine follow-ups is disrupted, making it difficult for them to control their disease.MethodsInternational databases, including PubMed/Medline, Web of Science, and Scopus, were searched until April 2022. All observational studies included assessing the impact of lockdown and social distancing on eating habits (as primary outcome), and glycemic and anthropometric indices (as secondary outcomes) of diabetic patients during the COVID-19 pandemic. The Newcastle-Ottawa Quality Scale was used to assess the quality rating of the studies.ResultsOverall, 22 studies were included in this systematic review, the results of which varied in different communities. In most studies, consumption of grains, fruits, and vegetables was reported to increase. On the other hand, consumption of snacks and sweets was reported to increase in other surveys. During the COVID-19 lockdown, most diabetic patients preferred to cook meals at home, using less takeout, fast foods, and alcoholic drinks. Although the patients mostly improved their eating habits, the glycemic and anthropometric indices were contradictory in different studies. Studies showed that the eating habits of diabetic patients vary from country to country, even in some cases and studies done in the same country showed different results. For example, all the studies done in Japan showed an increase in the consumption of snacks and sweets, leading to weight gain in the patients. However, conflicting results in eating habits have been observed in studies conducted in India.ConclusionThe lockdown policies have led to a beneficial change in the eating habits of diabetic patients to consume more fruits and vegetables and reduce the consumption of animal protein products and alcoholic beverages. While some diabetic patients have increased consumption of snacks and sweets, leading to a disturbance in their glycemic and anthropometric indices control. Understanding the consequences of lockdown and social distancing of the diabetic patient during the COVID-19 pandemic can help public health authorities make better recommendations to improve glycemic control.

Global Hospital Average Length of Stay for Diabetes Cases by Country, 2023 Discover more data with ReportLinker!

Human Insulin Regular Market Outlook

The global human insulin regular market size was valued at approximately $6.2 billion in 2023 and is projected to reach around $10.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.7%. The growth of this market is primarily driven by the increasing prevalence of diabetes worldwide, advancements in insulin delivery systems, and rising awareness about diabetes management. The market size is poised for substantial growth due to the increasing number of diabetic patients, improved healthcare infrastructure, and technological advancements in insulin administration.

The surge in diabetes cases, particularly Type 2 diabetes, is one of the major growth factors for the human insulin regular market. Sedentary lifestyles, unhealthy eating habits, and rising obesity rates contribute significantly to the increasing diabetes prevalence. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a number expected to rise considerably by 2030. This surge underscores the growing need for effective diabetes management solutions, thus driving the demand for human insulin regular.

Technological advancements and innovations in insulin delivery systems also play a crucial role in market growth. The development of insulin pens, smart insulin pumps, and continuous glucose monitoring systems has revolutionized diabetes management by offering more accurate and user-friendly options for insulin administration. These advancements not only improve patient compliance but also enhance the quality of life for diabetic patients. The integration of digital health solutions and artificial intelligence in diabetes care further propels the market growth, providing a more holistic and personalized approach to diabetes management.

Government initiatives and favorable reimbursement policies are another significant factor contributing to market growth. Many countries have implemented national diabetes programs aimed at early diagnosis, effective management, and prevention of diabetes-related complications. These initiatives often come with financial support for both patients and healthcare providers, making insulin more accessible and affordable. For instance, programs in the United States, Canada, and several European countries provide subsidies and insurance coverage for insulin, thereby encouraging more patients to adhere to their prescribed insulin regimens.

Regionally, North America holds a substantial share of the human insulin regular market due to the high prevalence of diabetes and well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period. Factors such as increasing urbanization, rising healthcare expenditure, and growing awareness about diabetes management contribute to this growth. The presence of a large diabetic population in countries like China and India also fuels the demand for human insulin regular in the Asia Pacific region.

Product Type Analysis

The human insulin regular market is segmented by product type into vials, cartridges, and prefilled pens. Vials have traditionally been the most commonly used form of insulin due to their cost-effectiveness and widespread availability. They have been the cornerstone of insulin therapy for decades, particularly in hospital settings where large quantities of insulin are required. Despite the advent of more advanced delivery systems, vials remain a popular choice, especially in lower-income regions where affordability is a significant concern.

Cartridges, on the other hand, offer a more convenient and portable option for insulin administration. They are typically used with insulin pens, which provide more precise dosing and ease of use compared to vials and syringes. This segment has seen significant growth due to the increasing preference for insulin pens among both patients and healthcare providers. The demand for cartridges is also driven by the growing trend towards home-based diabetes management, as they are more user-friendly and reduce the risk of dosage errors.

Prefilled pens represent the most advanced and convenient form of insulin delivery currently available. These devices come preloaded with insulin and are designed to be disposable after use, eliminating the need for vial and syringe handling. Prefilled pens are particularly beneficial for elderly patients or those with dexterity issues, as they simplify the injection process and improve adherence to insulin therapy. This segment is expe

This chart shows the rate of hospitalizations for short- term complications of diabetes for the most recent data year by age range and county. It also shows the 2017 objective by age range. This chart is based on one of three datasets related to the Prevention Agenda Tracking Indicators county level data posted on this site. Each dataset consists of county level data for 68 health tracking indicators and sub-indicators for the Prevention Agenda 2013-2017: New York State’s Health Improvement Plan. A health tracking indicator is a metric through which progress on a certain area of health improvement can be assessed. The indicators are organized by the Priority Area of the Prevention Agenda as well as the Focus Area under each Priority Area. Each dataset includes tracking indicators for the five Priority Areas of the Prevention Agenda 2013-2017. The most recent year dataset includes the most recent county level data for all indicators. The trend dataset includes the most recent county level data and historical data, where available. Each dataset also includes the Prevention Agenda 2017 state targets for the indicators. Sub-indicators are included in these datasets to measure health disparities among socioeconomic groups. For more information, check out: http://www.health.ny.gov/prevention/prevention_agenda/2013-2017/ and https://www.health.ny.gov/PreventionAgendaDashboard. The "About" tab contains additional details concerning this dataset.

Diabetic Food Market Outlook

According to our latest research, the global diabetic food market size reached USD 13.4 billion in 2024, reflecting robust consumer demand and increasing health awareness worldwide. The market is demonstrating a strong momentum with a recorded CAGR of 5.7% during 2024. This growth is primarily fueled by the rising prevalence of diabetes, shifting dietary patterns, and expanding product innovation. As per our projections, the market is expected to reach USD 21.2 billion by 2033, as manufacturers and retailers continue to cater to the evolving needs of diabetic consumers across the globe. The market's upward trajectory is underpinned by heightened health consciousness, government initiatives, and advances in food technology.

A significant growth factor for the diabetic food market is the alarming increase in diabetes prevalence worldwide. The International Diabetes Federation reports that over 537 million adults are living with diabetes globally, with numbers expected to rise in the coming years. This surge in diabetic cases has led to an amplified demand for specialized food products that help manage blood glucose levels without compromising taste or nutrition. Manufacturers are responding with innovative formulations, such as low-glycemic index ingredients and sugar substitutes, to make diabetic-friendly alternatives more accessible. Additionally, the growing awareness among consumers about the long-term health risks associated with high sugar intake has shifted preferences towards healthier food choices, further propelling market growth.

Technological advancements and product innovation are also playing a crucial role in driving the diabetic food market. Companies are investing heavily in research and development to create new product lines that cater to diabetic needs while maintaining flavor, texture, and nutritional value. The incorporation of natural sweeteners like stevia, monk fruit, and allulose is becoming increasingly common, replacing traditional sugars in bakery, confectionery, and beverage segments. Moreover, the rise of functional foods enriched with dietary fibers, proteins, and essential micronutrients is attracting health-conscious consumers, including those at risk of developing diabetes. This trend is further supported by strategic collaborations between food manufacturers and health organizations, emphasizing the importance of balanced diets for diabetes management.

Another key growth driver is the proactive role of governments and healthcare organizations in promoting diabetes awareness and healthy eating habits. Many countries have introduced regulations and guidelines to limit sugar consumption in processed foods, encouraging the food industry to reformulate their products. Public health campaigns and educational programs are also instrumental in informing consumers about the benefits of diabetic-friendly diets. In addition, the increasing availability of diabetic food products through diverse distribution channels, including online stores and specialty outlets, has made it easier for consumers to access these products. This multi-faceted approach, combining regulatory support, public awareness, and enhanced product availability, is expected to sustain the market's growth trajectory in the coming years.

From a regional perspective, North America continues to dominate the diabetic food market, driven by a high prevalence of diabetes, advanced healthcare infrastructure, and strong consumer purchasing power. Europe follows closely, with a significant market share attributed to stringent food safety regulations and a well-established retail sector. The Asia Pacific region is emerging as a high-growth market, fueled by rapid urbanization, rising disposable incomes, and increasing health awareness among the population. Latin America and the Middle East & Africa are also witnessing steady growth, supported by ongoing public health initiatives and expanding distribution networks. Overall, the global diabetic food market is poised for sustained expansion, with regional dynamics playing a pivotal role in shaping its future landscape.